Sun Pharma will acquire Japan based
Polo Pharma for around $1 Million to strengthen its presence in dermatology
segment across the globe. The company has entered into a definitive agreement
to acquire Pola Pharma, which is engaged in research and development,
manufacture, sale and distribution of branded and generic products in Japan.
Pola Pharma portfolio mainly
comprises dermatology products. It has two manufacturing facilities
in Saitama with capabilities to manufacture topical products and injectables. It
also has R&D capabilities to develop new technologies and formulations. Pola
Pharma is a leading dermatology company and it will help Sun Pharma launch our specialty
and generic dermatology products in the Japanese market in future.
Sun
Pharma forayed into the Japanese prescription market in 2016, with the
acquisition of 14 established prescription brands from Novartis. The size of
the Japanese pharmaceutical market is estimated at $84.8 billion, accounting
for around 7.5% of the $1.13-trillion global pharmaceutical market.
No comments:
Post a Comment